Daniel De Murat
Overview
Explore the profile of Daniel De Murat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
9
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Violon F, Bouys L, Vaduva P, Chansavang A, Vaquier L, Letourneur F, et al.
Endocr Pathol
. 2024 Aug;
35(3):194-206.
PMID: 39180662
Bilateral macronodular adrenocortical disease (BMAD) is an uncommon cause of Cushing's syndrome leading to bilateral macronodules. Isolated BMAD has been classified into three molecular groups: patients with ARMC5 alteration, KDM1A...
2.
Birtolo M, Armignacco R, Benanteur N, Baussart B, Villa C, De Murat D, et al.
Eur J Endocrinol
. 2024 Jul;
191(1):55-63.
PMID: 38970559
Objective: Cushing's syndrome is characterized by high morbidity and mortality with high interindividual variability. Easily measurable biomarkers, in addition to the hormone assays currently used for diagnosis, could reflect the...
3.
Armignacco R, Carlier N, Jouinot A, Birtolo M, De Murat D, Tubach F, et al.
Funct Integr Genomics
. 2024 May;
24(3):107.
PMID: 38772950
COVID-19 is associated with heterogeneous outcome. Early identification of a severe progression of the disease is essential to properly manage the patients and improve their outcome. Biomarkers reflecting an increased...
4.
Jouinot A, Lippert J, Sibony M, Violon F, Jeanpierre L, De Murat D, et al.
Eur J Endocrinol
. 2022 Mar;
186(6):607-617.
PMID: 35266879
Design: Molecular classification is important for the diagnosis and prognosis of adrenocortical tumors (ACT). Transcriptome profiles separate adrenocortical adenomas 'C2' from carcinomas, and identify two groups of carcinomas 'C1A' and...
5.
Romanet P, Galluso J, Kamenicky P, Hage M, Theodoropoulou M, Roche C, et al.
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34299200
Forty percent of somatotroph tumors harbor recurrent activating mutations, historically called the oncogene. In -negative somatotroph tumors, expression itself is highly variable; those with overexpression most resemble phenotypically those carrying...